Who was sanctioned, and for what?

From 2018 to 2021, the pharmaceutical manufacturer allegedly used two patient assistance foundations to fund Medicare beneficiaries’ co-payments for its drug Oxervate in order to promote its sales. Following a self-disclosure, Dompé paid 32 million USD.

Authority / court

U.S. Department of Justice / U.S. Attorney's Office, District of Massachusetts

Area of law

Bribery and corruption · Gifts, hospitality and benefits

Legal basis

Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)); False Claims Act (31 U.S.C. §§ 3729 ff.)

Action

Other

Status of proceedings

final

Sector

Chemicals and pharmaceuticals

Mitigating circumstances

Self-disclosure.

Original amount 32,000,000 USD, converted at the ECB reference rate of 10 Sep 2026.

Checked against the official source on 25 Sep 2026 · Direct link

From 2016 to 2023, Veloxis provided transplant professionals with expensive meals and alcohol, trips and stays at luxury resorts, gifts and consultancy fees without consideration, and paid specialty pharmacies concealed remuneration in order to promote prescriptions and purchases of the immunosuppressant Envarsus XR. The company entered into a Deferred Prosecution Agreement with a criminal payment of more than 10 million USD, is paying 34.45 million USD under civil law (21,211,251 USD to the federal government, 13,238,749 USD to states) and a penalty of 1.55 million USD under the Sunshine Act (Open Payments) – the highest to date – totalling over 46 million USD.

Authority / court

U.S. Department of Justice / U.S. Attorney's Office, District of Massachusetts

Area of law

Bribery and corruption · Gifts, hospitality and benefits

Legal basis

Anti-Kickback Statute; False Claims Act; Physician Payments Sunshine Act (Open Payments)

Action

Other

Status of proceedings

final

Sector

Chemicals and pharmaceuticals

Checked against the official source on 25 Sep 2026 · Direct link

From 2014 to 2020, Takeda allegedly selected physicians specifically for its speaker programme for the antidepressant Trintellix and provided them with fees and meals at expensive restaurants to promote prescriptions; some participants attended the same event several times without any educational benefit. Takeda paid 13,670,921 USD.

Authority / court

U.S. Department of Justice / U.S. Attorney's Office, Eastern District of California

Area of law

Bribery and corruption · Gifts, hospitality and benefits

Legal basis

Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)); False Claims Act (31 U.S.C. §§ 3729 ff.)

Action

Other

Status of proceedings

final

Sector

Chemicals and pharmaceuticals

Employees

10,000 or more

Original amount 13,670,921 USD, converted at the ECB reference rate of 14 May 2026.

Checked against the official source on 25 Sep 2026 · Direct link

Following its 2020 guilty plea, the opioid manufacturer was sentenced in Newark to a criminal fine of 3.544 billion USD (asserted in the insolvency proceedings) and forfeiture of 2 billion USD; up to 1.775 billion USD can be credited against the forfeiture if Purdue emerges from insolvency as a public benefit company. Purdue had deceived the DEA and paid kickbacks to prescribers via its speaker programme and to an electronic health records platform in order to increase opioid prescriptions.

Authority / court

U.S. District Court, District of New Jersey (Anklage: U.S. Department of Justice)

Area of law

Bribery and corruption · Gifts, hospitality and benefits

Legal basis

Verschwörung zum Betrug der USA und zur Verletzung des Food, Drug, and Cosmetic Act; zwei Fälle Verschwörung zur Verletzung des Anti-Kickback Statute (Schuldbekenntnis vom 24.11.2020)

Action

Fine

Status of proceedings

unknown

Sector

Chemicals and pharmaceuticals

Culpability

intentional

Original amount 5,544,000,000 USD, converted at the ECB reference rate of 28 Apr 2026.

Checked against the official source on 25 Sep 2026 · Direct link

On an application by the Australian Securities and Investments Commission (ASIC), the Federal Court of Australia allegedly imposed civil penalties totalling 925,000 AUD: 575,000 AUD on the licensee R M Capital and 350,000 AUD on its authorised representative The SMSF Club. Between November 2014 and July 2016 SMSF Club accepted referral fees totalling 135,863.65 AUD (excluding GST) on 52 occasions from a property provider that referred clients to it, who then set up self-managed superannuation funds (SMSFs) with its help and used them to buy property from that provider; the court treated this as prohibited conflicted remuneration, and R M Capital, as licensee, had through gross negligence failed to take reasonable steps to prevent it. Both companies must provide ASIC with an independent expert's report on their compliance arrangements within six months; R M Capital lodged an appeal on 15 January 2026. The decision is not final.

Authority / court

Federal Court of Australia (Verfahren der Australian Securities and Investments Commission, ASIC)

Area of law

Bribery and corruption · Gifts, hospitality and benefits

Legal basis

Corporations Act 2001 (Cth) s 963F, s 963G(1), s 1317G(1E), s 1101B(1)(a)(i)

Action

Fine

Status of proceedings

under appeal

Sector

Financial services and insurance

Culpability

negligent

Repeat case

no

Mitigating circumstances

For SMSF Club, ASIC and the company submitted as mitigating that it ended the referral arrangement immediately after ASIC raised concerns in 2016, cooperated and agreed to resolve the matter, that these were the first contraventions alleged against it and that no client loss was alleged; the court allegedly approved the jointly proposed penalty.

Published

19 Dec 2025

Original amount 925,000 AUD, converted at the ECB reference rate of 18 Dec 2025.

Checked against the official source on 3 Oct 2026 · Direct link

The Minnesota provider of outpatient addiction treatment pays USD 18,500,000 to resolve False Claims Act allegations and entered into a five-year Corporate Integrity Agreement with HHS-OIG. According to the US Attorney's Office, from January 2019 to February 2025 NUWAY compensated Medicaid patients for attending intensive outpatient treatment and also billed services in which the same period of time was counted twice. The authority allegedly made the findings set out here; this account is not based on a final judgment.

Authority / court

U.S. Attorney's Office, District of Minnesota (U.S. Department of Justice)

Area of law

Bribery and corruption · Gifts, hospitality and benefits

Legal basis

False Claims Act; Anti-Kickback Statute

Action

Other

Status of proceedings

final

Sector

Healthcare

Published

26 Jun 2025

Original amount 18,500,000 USD, converted at the ECB reference rate of 26 Jun 2025.

Checked against the official source on 3 Oct 2026 · Direct link

Gilead paid physicians who spoke at or attended events on its HIV medicines fees, meals and travel expenses to promote prescriptions; high prescribers received hundreds of thousands of dollars, and events took place at luxury restaurants. The court-approved settlement of 202 million USD contains extensive admissions of fact.

Authority / court

U.S. Attorney's Office, Southern District of New York; U.S. District Court (S.D.N.Y.)

Area of law

Bribery and corruption · Gifts, hospitality and benefits

Legal basis

Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)); False Claims Act (31 U.S.C. §§ 3729 ff.)

Action

Other

Status of proceedings

final

Sector

Chemicals and pharmaceuticals

Employees

10,000 or more

Published

29 Apr 2025

Original amount 202,000,000 USD, converted at the ECB reference rate of 28 Apr 2025.

Checked against the official source on 25 Sep 2026 · Direct link

Pfizer pays USD 59,746,277 on behalf of its subsidiary Biohaven to resolve False Claims Act and Anti-Kickback Statute allegations relating to the period before the acquisition; about USD 50.2 million goes to the federal government and about USD 9.5 million to state Medicaid programmes. From March 2020 to September 2022 Biohaven allegedly gave selected doctors speaker fees and meals at expensive restaurants to encourage prescriptions of the migraine drug Nurtec ODT; some events were attended repeatedly by the same doctors or by spouses, relatives and practice colleagues with no educational need.

Authority / court

U.S. Department of Justice (Civil Division; USAO Western District of New York)

Area of law

Bribery and corruption · Gifts, hospitality and benefits

Legal basis

False Claims Act; Anti-Kickback Statute

Action

Other

Status of proceedings

final

Sector

Chemicals and pharmaceuticals

Employees

10,000 or more

Published

24 Jan 2025

Original amount 59,746,277 USD, converted at the ECB reference rate of 24 Jan 2025.

Checked against the official source on 3 Oct 2026 · Direct link

Bard and three affiliated companies pay USD 17 million to resolve allegations under the federal False Claims Act and several state statutes. Between 2016 and February 2020 they allegedly gave urology practices discounts, excessive free samples and savings on office supplies so that they would prescribe intermittent catheters by default using Bard's own “Link” prescription form; no liability was determined.

Authority / court

U.S. Attorney's Office, Northern District of Georgia (U.S. Department of Justice)

Area of law

Bribery and corruption · Gifts, hospitality and benefits

Legal basis

False Claims Act; Anti-Kickback Statute (42 U.S.C. § 1320a-7b); False-Claims-Gesetze mehrerer Bundesstaaten

Action

Other

Status of proceedings

final

Sector

Healthcare

Published

23 Jan 2025

Original amount 17,000,000 USD, converted at the ECB reference rate of 23 Jan 2025.

Checked against the official source on 3 Oct 2026 · Direct link

The Puerto Rico Medicare Advantage provider pays USD 15,228,340 to resolve False Claims Act and Anti-Kickback Statute allegations and entered into a five-year Corporate Integrity Agreement with HHS-OIG. From January 2018 to December 2022 MMM allegedly gave gift cards to administrative assistants of medical practices so that they would get thousands of Medicare beneficiaries to enrol in an MMM plan; the resulting premium payments amounted to USD 6,091,336.

Authority / court

U.S. Attorney's Office, District of Puerto Rico; HHS Office of Inspector General (HHS-OIG)

Area of law

Bribery and corruption · Gifts, hospitality and benefits

Legal basis

False Claims Act; Anti-Kickback Statute

Action

Other

Status of proceedings

final

Sector

Financial services and insurance

Mitigating circumstances

The company's cooperation and its implementation of internal controls were taken into account.

Published

23 Dec 2024

Original amount 15,228,340 USD, converted at the ECB reference rate of 23 Dec 2024.

Checked against the official source on 3 Oct 2026 · Direct link

From 2017 to 2020, the acquired Thai subsidiary provided public officials, including officials of the Royal Thai Air Force and the Department of Highways, with cash, sham consultancy fees, luxurious "factory visit trips", meals and entertainment, and also engaged in commercial bribery. The group is paying 4,343,401 USD in disgorgement, 1,086,954 USD in interest and a penalty of 4.5 million USD.

Authority / court

U.S. Securities and Exchange Commission (SEC)

Area of law

Bribery and corruption · Gifts, hospitality and benefits

Legal basis

FCPA Buchführungs- und interne Kontrollvorschriften (Sections 13(b)(2)(A)/(B) Exchange Act)

Action

Fine

Status of proceedings

final

Sector

Manufacturing and mechanical engineering

Employees

10,000 or more

Culpability

intentional

Published

10 Sep 2024

Original amount 9,930,355 USD, converted at the ECB reference rate of 10 Sep 2024.

Checked against the official source on 28 Sep 2026 · Version 5 · Company name anonymised since 10 Sep 2026 · Direct link

From 2014 to 2018, employees of the group's Chinese subsidiary invited healthcare officials of state-owned customers abroad to purported conferences and training courses that in reality often consisted of sightseeing and entertainment; payment was made via a complicit travel agency. Payment of 3,538,897 USD in disgorgement, 1,042,721 USD in interest and a penalty of 2 million USD.

Authority / court

U.S. Securities and Exchange Commission (SEC)

Area of law

Bribery and corruption · Gifts, hospitality and benefits

Legal basis

FCPA Buchführungs- und interne Kontrollvorschriften

Action

Fine

Status of proceedings

final

Sector

Healthcare

Employees

10,000 or more

Culpability

intentional

Mitigating circumstances

Prompt self-report upon becoming aware, cooperation (including witnesses and documents) and extensive remedial measures.

Published

25 Aug 2023

Original amount 6,581,618 USD, converted at the ECB reference rate of 25 Aug 2023.

Checked against the official source on 28 Sep 2026 · Version 4 · Company name anonymised since 25 Aug 2025 · Direct link

The Országos Gyógyszerészeti és Élelmezés-egészségügyi Intézet (OGYÉI, Hungarian National Institute of Pharmacy and Nutrition) fined a Hungarian pharmaceutical company 37,000,000 HUF and prohibited continuation of the infringements, because the company had in numerous cases granted prescribing doctors unlawful financial benefits through fee contracts – for example for role-plays used to train its own sales representatives, specialist articles for a company-branded promotional publication, promotional lectures, and paid lectures given by heads of department to their own staff. In addition, hospitality exceeded the statutory per-head limit in four cases at its own professional events, support enabling doctors to attend two international professional events was not reported, and there were shortcomings concerning warning symbols in promotional material, the handing out of samples and donation records. The decision was issued in new proceedings after the Fővárosi Törvényszék (Budapest-Capital Regional Court) had annulled an earlier 2020 decision for inadequate reasoning on the amount of the sanction, while upholding the legal assessment of the fee contracts.

Authority / court

Országos Gyógyszerészeti és Élelmezés-egészségügyi Intézet (OGYÉI; Rechtsnachfolger NNGYK)

Area of law

Bribery and corruption · Gifts, hospitality and benefits

Legal basis

Gyftv. (Gesetz Nr. XCVIII/2006) § 14 Abs. 1, 2 und 10, § 11/B Abs. 2, § 19 Abs. 2 lit. c und d; EüM-Verordnung 3/2009 § 7 Abs. 1 lit. a, § 10 Abs. 3

Action

Fine

Status of proceedings

final

Sector

Chemicals and pharmaceuticals

Published

28 Jul 2023

Original amount 37,000,000 HUF, converted at the ECB reference rate of 28 Jul 2023.

Checked against the official source on 28 Sep 2026 · Company name anonymised since 28 Jul 2025 · Direct link